Share this article

Position document: Management of biofilm

Greg Shultz, Isabelle Fromantin, Klaus Kirketerp-Mølle, Randall D Wolcott, Thomas Bjarnsholt
22 September 2016

Antimicrobial and multi-drug resistance loom large on the global healthcare landscape, in particular in the treatment of chronic, hard-toheal wounds where current figures put the presence of biofilm in 60%–100% of non-healing wounds. While the role that biofilm play in the chronicity of wounds is still in infancy, it is becoming widely accepted that hard-to-heal wounds contain biofilm — and that somehow their presence delays or prevents healing.

​Supported by B Braun

Free for all healthcare professionals

Sign up to the Wounds Group journals

By clicking ‘Subscribe’, you are agreeing that the Wounds Group are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our privacy policy.

Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.

We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.

I am not a healthcare professional.